All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

  TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Panobinostat works synergistically with daratumumab by up-regulating CD38

By Fiona Chaplin

Share:

May 17, 2017


Panobinostat is a HDAC inhibitor used to treat multiple myeloma (MM) and effects expression of several critical genes. The question of its mechanism of action on myeloma cells was addressed in a letter to the editor of Blood, published in May 2017. Estefania Garcia-Guerrero and colleagues from Medizinische Klinik and Poliklinik II, University of Würzburg, Germany, and Institute of Biomedicine Seville, IBIS Hospital, University of Seville, Spain, showed that panobinostat specifically up-regulates CD38 on MM cells and that this increase augments the effect of the monoclonal antibody daratumumab.

Key Findings:

Up-regulation of CD38:

  • Uniform increase in CD38 was observed on primary myeloma cells (n= 12 patients) in response to panobinostat titration (0-25 nM)
  • Expression increased after 24 hrs with a peak at 48 hrs
  • Mean Fluorescence Intensity (MFI) was 3 fold (10nM) and 5-fold (25nM) higher than untreated myeloma at 48 hrs (p<0.01)
  • CD38 up-regulation was uniform across patients (pts) with newly diagnosed MM (n=5), relapsed and refractory MM (RRMM) (n=7)
  • Enhanced expression was confirmed in two MM cell lines – MM1.S and OPM-2
  • CD38 levels returned to baseline 24 hrs after withdrawal of panobinostat; re-exposure increased CD38 to comparable levels
  • The effect was myeloma cell specific; no increase in CD38 on other lymphoma cell lines

Synergy with daratumumab:

  • Primary myeloma cells (n=4 patients) were treated with panobinostat for 48 hours at 10 nM
  • Daratumumab or control antibody was then added, along with patient-derived autologous PBMC
  • Significant increase in ADCC (4 hr assay) observed for panobinostat treated vs untreated cells
  • Percentage of panobinostat-treated primary myeloma cells eliminated by daratumumab = 78% vs 51% without panobinostat treatment (p<0.01)
  • This effect was confirmed with the MM1.S myeloma cell line (panobinostat-treated vs untreated plus daratumumab): after 4 hours = 45% vs 26%; after 20 hrs: 89% vs 64%; (n=3 experiments, p<0.0001)
  • This effect primarily occurs via antibody dependent cell-mediated cytotoxicity (ADCC); no complement dependent cytotoxicity (CDC) was observed
  • CD38 up-regulation was not observed across other cell types (eg. T cells), indicating specificity for myeloma cells

In conclusion, the ability of panobinostat to selectively up-regulate CD38 on myeloma cells provided a synergistic effect when administered with daratumumab, and warrants further investigation of this dual treatment regimen.

References

Your opinion matters

Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?